Holen Sie sich die Stockscreener-App
94.65
0.86%
-0.82
Handel nachbörslich:
94.00
-0.65
-0.69%
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte gears up to report Q1 earnings: What can investors expect? - MSN
Incyte, BNY Mellon, Quantum-Si, Jabil, Levi Shock - TipRanks
Munich Reinsurance Co Stock Corp in Munich Invests $6.07 Million in Incyte Corporation $INCY - MarketBeat
Incyte Corporation $INCY Shares Purchased by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
FDA calls out Incyte’s Niktimvo efficacy claims on branded website - Medical Marketing and Media
Incyte Gears Up to Report Q1 Earnings: What Can Investors Expect? - The Globe and Mail
INCY Stock Price, Quote & Chart | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte Q1 Preview: The Growth Story Remains Intact (NASDAQ:INCY) - Seeking Alpha
Ruffer LLP Has $2.51 Million Holdings in Incyte Corporation $INCY - MarketBeat
MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia - Financial Times
Incyte (INCY) Stock Analysis | Incyte Corp Posts 8.5% EPS Miss Vs Consensus ViewsMost Discussed Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Incyte Corporation $INCY Stock Holdings Raised by Zurcher Kantonalbank Zurich Cantonalbank - MarketBeat
31,459 Shares in Incyte Corporation $INCY Bought by CPC Advisors LLC - MarketBeat
INCY Financials: Income Statement, Balance Sheet & Cash Flow | Incyte Corp - Stock Titan
Incyte president, R&D head sells $1.8m in stock, acquires $1.2m in shares - Investing.com
INCYTE CORP (INCY) executive exercises options and sells 18,667 shares - Stock Titan
Incyte (INCY) to Present Phase 3 Tafasitamab Study Results at AS - GuruFocus
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 Americ - The National Law Review
Incyte to present tafasitamab lymphoma study results at ASCO - Investing.com
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - Business Wire
Incyte discloses new TYK2 and/or JAK1 inhibitors - BioWorld News
Incyte (INCY) Projected to Post Earnings on Tuesday - MarketBeat
Assetmark Inc. Raises Holdings in Incyte Corporation $INCY - MarketBeat
Incyte to Report Q1 Results on April 28 - MyChesCo
Adagene and Incyte Partner to Develop Colorectal Cancer Therapy - HarianBasis.co
Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer - Insider Monkey
Assessing Incyte (INCY) Valuation As Recent Returns Send Mixed Signals - Yahoo Finance
Here's Why Incyte (INCY) is a Strong Value Stock - Yahoo Finance
Incyte Corp. (NASDAQ:INCY) Presents a Compelling Value Investment Case - ChartMill
RBC Capital Lifts PT on Incyte Corporation (INCY) to $95 From $92 - Insider Monkey
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
INCYTE (NASDAQ: INCY) CEO granted 125,000 performance-based common shares - Stock Titan
INCYTE (INCY) R&D president earns 27,892 performance shares in equity award - Stock Titan
Incyte (NASDAQ: INCY) CMO earns 39,049 performance-based share award - Stock Titan
INCY (NASDAQ: INCY) Form 144 lists 18,667-share option exercise and prior sales - Stock Titan
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte Shares Dip as Major Investor Reduces Stake - National Today
Incyte Corporation $INCY Holdings Lowered by Massachusetts Financial Services Co. MA - MarketBeat
Do Options Traders Know Something About Incyte Stock We Don't? - Yahoo Finance
INCY Reiterates by HC Wainwright & Co. -- Price Target Maintained at $135 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on hidradenitis drug - Investing.com
Incyte's (INCY) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
28,383 Shares in Incyte Corporation $INCY Purchased by Monument Capital Management - MarketBeat
Here's What to Expect From Incyte’s Next Earnings Report - Barchart.com
Robeco Institutional Asset Management B.V. Increases Stake in Incyte Corporation $INCY - MarketBeat
Beacon Harbor Wealth Advisors Boosts Incyte Corporation Holdings - National Today
INCYTE CORP (NASDAQ:INCY) Presents a High-Growth Momentum Breakout Setup - ChartMill
Q4 2025 Incyte Corp Earnings Call Transcript - GuruFocus
Incyte Corp stock: What investors should know about its biotech potential now - AD HOC NEWS
Incyte to Report First Quarter 2026 Financial Results - National Today
L2 Asset Management, LLC's Incyte Corp(INCY) Holding History - GuruFocus
Incyte Corporation (INCY) stock price, news, quote and history - Yahoo Finance UK
Incyte to Report First Quarter Financial Results - ChartMill
Barclays Maintains Overweight on Incyte Corporation (INCY) March 24, 2026 - Meyka
Incyte Corp. stock rises Wednesday, still underperforms market - MarketWatch
4.01%
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):